Miller D - Search Results

1

Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.

Bishop JR, Ellingrod VL, Moline J, Miller D. Bishop JR, et al. Among authors: miller d. Schizophr Res. 2005 Sep 15;77(2-3):253-60. doi: 10.1016/j.schres.2005.04.001. Schizophr Res. 2005. PMID: 15913960

2

Effect of antipsychotic withdrawal on negative symptoms in schizophrenia.

Miller DD, Flaum M, Arndt S, Fleming F, Andreasen NC. Miller DD, et al. Neuropsychopharmacology. 1994 Aug;11(1):11-20. doi: 10.1038/npp.1994.31. Neuropsychopharmacology. 1994. PMID: 7945739

3

The life course of schizophrenia: age and symptom dimensions.

Schultz SK, Miller DD, Oliver SE, Arndt S, Flaum M, Andreasen NC. Schultz SK, et al. Among authors: miller dd. Schizophr Res. 1997 Jan 17;23(1):15-23. doi: 10.1016/S0920-9964(96)00087-4. Schizophr Res. 1997. PMID: 9050124

4

A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.

Ho BC, Miller D, Nopoulos P, Andreasen NC. Ho BC, et al. Among authors: miller d. J Clin Psychiatry. 1999 Oct;60(10):658-63. doi: 10.4088/jcp.v60n1003. J Clin Psychiatry. 1999. PMID: 10549681 Clinical Trial.

5

CYP2D6 polymorphisms and atypical antipsychotic weight gain.

Ellingrod VL, Miller D, Schultz SK, Wehring H, Arndt S. Ellingrod VL, et al. Among authors: miller d. Psychiatr Genet. 2002 Mar;12(1):55-8. doi: 10.1097/00041444-200203000-00008. Psychiatr Genet. 2002. PMID: 11901361

6

5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia.

Ellingrod VL, Perry PJ, Lund BC, Bever-Stille K, Fleming F, Holman TL, Miller D. Ellingrod VL, et al. Among authors: miller d. J Clin Psychopharmacol. 2002 Dec;22(6):622-4. doi: 10.1097/00004714-200212000-00014. J Clin Psychopharmacol. 2002. PMID: 12454564 Clinical Trial. No abstract available.

7

5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia.

Ellingrod VL, Lund BC, Miller D, Fleming F, Perry P, Holman TL, Bever-Stille K. Ellingrod VL, et al. Among authors: miller d. Psychopharmacol Bull. 2003 Spring;37(2):109-12. Psychopharmacol Bull. 2003. PMID: 14566219 Clinical Trial.

8

Distribution of the serotonin 2C (5HT2C) receptor gene -759C/T polymorphism in patients with schizophrenia and normal controls.

Ellingrod VL, Miller D, Ringold JC, Perry PJ. Ellingrod VL, et al. Among authors: miller d. Psychiatr Genet. 2004 Jun;14(2):93-5. doi: 10.1097/01.ypg.0000107930.32051.8e. Psychiatr Genet. 2004. PMID: 15167695

9

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism.

Miller DD, Ellingrod VL, Holman TL, Buckley PF, Arndt S. Miller DD, et al. Am J Med Genet B Neuropsychiatr Genet. 2005 Feb 5;133B(1):97-100. doi: 10.1002/ajmg.b.30115. Am J Med Genet B Neuropsychiatr Genet. 2005. PMID: 15635667

10

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine.

Ellingrod VL, Perry PJ, Ringold JC, Lund BC, Bever-Stille K, Fleming F, Holman TL, Miller D. Ellingrod VL, et al. Among authors: miller d. Am J Med Genet B Neuropsychiatr Genet. 2005 Apr 5;134B(1):76-8. doi: 10.1002/ajmg.b.20169. Am J Med Genet B Neuropsychiatr Genet. 2005. PMID: 15666332 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14,636 results

Search Page

Filters